The first phase 3 trial of a broadly acting RAS inhibitor in metastatic pancreatic adenocarcinoma extended median survival to 13.2 months from 6.7 months with standard chemotherapy, a result that led the Food and Drug Administration to approve daraxonrasib on Aug. 26. Sold as Rasonque, the once-daily tablet is the first therapy designed to inhibit multiple active forms of RAS, a family of proteins that drives most pancreatic adenocarcinomas.

The approval covers adults whose cancer has spread and progressed after at least one systemic treatment, as well as patients who cannot tolerate multiagent therapy. It does not make daraxonrasib a first-line treatment, a cure or a replacement for surgery in earlier disease. Its immediate value is narrower and still substantial: a new option for people whose metastatic cancer has already outgrown the treatment most likely to control it.

The stakes are unusually high. Federal estimates project 67,530 U.S. pancreatic cancer diagnoses and 52,740 deaths in 2026. Only 13.7% of patients live at least five years after diagnosis, and survival falls to 3.4% when the disease is already distant. Those population figures include several pancreatic cancers, but ductal adenocarcinoma accounts for roughly 90% to 95% of cases and is the tumor type covered by the new approval.

A Survival Gain in a Difficult Setting

The pivotal RASolute 302 trial enrolled 500 adults whose metastatic pancreatic adenocarcinoma had progressed after one prior line of systemic therapy. Participants were randomly assigned to daraxonrasib or a physician-selected chemotherapy regimen. The study was open-label, meaning patients and treating clinicians knew which therapy was given, but tumor scans used for progression assessments were reviewed centrally and without that knowledge.

Overall survival, the hardest endpoint to misinterpret, favored daraxonrasib. The hazard ratio for death was 0.40, corresponding to a 60% lower risk during the trial period; median survival was 13.2 months with the pill and 6.7 months with chemotherapy. Median progression-free survival was 7.2 months versus 3.6 months, and 30% of daraxonrasib recipients had a measurable tumor response compared with 11% in the chemotherapy group. All three differences were statistically significant.

The peer-reviewed report also matters because median survival is not a promise to an individual patient. It is the point at which half of each study group remained alive, and it does not establish how long the longest responders will benefit. Still, in a disease where incremental gains are common and second-line options are limited, the magnitude and consistency of the survival, progression and response findings make this more than a regulatory milestone.

How Daraxonrasib Reaches RAS

RAS proteins act like molecular switches. When bound to GTP, they turn on signals that promote cell growth; cancer-causing mutations can keep that signal active. KRAS mutations are present in more than 90% of pancreatic adenocarcinomas, yet their smooth protein surface and rapidly changing shape long frustrated attempts to design drugs that would bind reliably.

Daraxonrasib takes a different route from earlier inhibitors aimed at one mutation. According to the drug’s chemistry paper, it first helps form a three-part complex among the medicine, the intracellular protein cyclophilin A and active RAS. That complex blocks RAS from engaging the downstream proteins that carry its growth signal. Because the binding pocket uses features shared across several mutant and wild-type RAS forms, the drug can act more broadly than mutation-specific agents.

That breadth shaped the trial and the label. RASolute 302 included patients with and without an identified RAS mutation, and the FDA found significant benefit both in the prespecified RAS G12 group and in the full population. The approved indication therefore does not require a particular RAS result or a companion diagnostic. Molecular testing remains useful for understanding a tumor and identifying trials, but access to daraxonrasib is not limited to one KRAS subtype.

The Approval Has Clear Boundaries

The FDA authorized 300 milligrams by mouth once daily until the cancer progresses or toxicity becomes unacceptable. Eligible patients must have metastatic pancreatic adenocarcinoma and either have received prior systemic therapy or be unable to receive a multiagent regimen. People with localized or surgically removable disease, and patients doing well on first-line combination therapy, were not the population tested in the pivotal comparison.

That distinction prevents a strong second-line result from being generalized too far. A drug can perform differently when used earlier, when paired with chemotherapy or when given to patients with better organ function and fewer prior toxicities. Trials in additional pancreatic cancer settings and other RAS-driven tumors may expand the medicine’s role, but those questions require their own randomized evidence.

The approval was completed about 6.5 months before the FDA’s goal date using several expedited programs. It was also reviewed with Health Canada through Project Orbis, while European and Japanese regulators observed. Faster review changes when a treatment reaches patients; it does not change the evidentiary standard reported for this full approval.

Safety Requires Active Management

An oral drug is not automatically a mild drug. The prescribing information warns about severe skin and soft-tissue reactions, mouth inflammation, diarrhea, gastrointestinal perforation, interstitial lung disease or pneumonitis, and fetal harm. In the sponsor’s safety summary, dermatologic toxicity occurred in 86% of treated pancreatic cancer patients and was grade 3 in 10%; stomatitis occurred in 57%, including 9% at grade 3; and diarrhea occurred in 63%, including 6% at grade 3.

Less common events can be more dangerous. Gastrointestinal perforation occurred in 0.9% of patients, including one fatal case, and interstitial lung disease or pneumonitis occurred in 2.4%, also with one fatal event. The label recommends preventive skin care, close monitoring and treatment interruption, dose reduction or discontinuation according to severity. Those requirements make oncology follow-up essential even when the medicine is taken at home.

Patient-reported outcomes nevertheless favored daraxonrasib over chemotherapy. An ASCO summary reported a median 9.2 months before pain worsened, versus 3.8 months with chemotherapy, and 5.7 months before global health status or quality of life deteriorated, versus 2.6 months. Because the trial was open-label and company-funded, subjective outcomes deserve more caution than survival; their alignment with the objective results is nonetheless encouraging.

Price Will Shape Real-World Access

Revolution Medicines set a U.S. list price of $39,800 for a 30-day supply, according to Reuters. That figure is not the same as the net amount insurers pay or the out-of-pocket bill for an insured patient. Coverage rules, specialty-pharmacy distribution, deductibles, coinsurance and eligibility for manufacturer assistance will determine whether the treatment is promptly available in practice.

Demand was visible before approval. More than 2,000 patients entered an expanded-access program after the FDA allowed it to proceed in May, Reuters reported. That pathway addressed urgent need while review continued, but routine commercial use will shift the burden to oncology practices, payers and pharmacies that must verify eligibility, manage authorization and monitor toxicities without delaying treatment.

What Comes Next

The approval establishes that broadly inhibiting active RAS can improve survival in a randomized pancreatic cancer trial. It does not establish the best sequence with first-line chemotherapy, the value of combinations, the durability of benefit beyond current follow-up or whether the same advantage will appear in other RAS-driven cancers. Resistance is expected to emerge in at least some tumors, making post-progression samples and circulating tumor DNA important for the next generation of studies.

For patients and clinicians now, the practical change is immediate: there is a validated oral option after prior systemic therapy, with a survival advantage large enough to alter second-line discussions. The responsible interpretation is neither to understate the breakthrough nor oversell it. Daraxonrasib moves a target once described as undruggable into standard treatment, while leaving the central work of earlier detection, broader access, toxicity management and eventual resistance unfinished.